English Polski
Vol 26, No 1 (2020)
Review paper
Published online: 2020-03-25

open access

Page views 2007
Article views/downloads 1241
Get Citation

Connect on Social Media

Connect on Social Media

Selected biomarkers of atherosclerosis - clinical aspects

Stanisław Surma1, Tomasz Czober2, Tomasz Lepich1, Oskar Sierka1, Grzegorz Bajor1
Acta Angiologica 2020;26(1):28-39.


Atherosclerosis is a inflammatory-immunological-degenerative process. Cardiovascular diseases account for 42% of premature deaths among men and 52% of premature deaths among woman. Identification of classical biomarkers of atherosclerosis, such as LDL, HDL and triglycerides may not be helpful in patients with moderate or unusual cardiovascular risk. Non-classical indicators of atherosclerosis include markers of the inflammatory proces, mar-kers of atherosclerotic plaque injury, acute phase proteins, ischemic markers, markers of tissue necrosis, markers of myocardial dysfunction. The identification of CVD biomarkers enables the classification of patients to appropriate cardiovascular risk groups. Knowledge about the CVD risk group makes it possible to take rapid therapeutic intervention aimed at limiting this risk. Pharmacotherapy for cardiovascular diseases is primarily based on lowering cholesterol’s level in the blood. Additional properties of statins (the most important lipid-lowering drugs) enable their pleiotropic effect by limiting the progression of atherosclerotic lesions by reducing the volume of atherosclerotic plaque. Further research on the pathogenesis of atherosclerosis will allow to learn new risk factors and new biomarkers of this disease.

Article available in PDF format

View PDF Download PDF file


  1. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med. 2002; 21(2): 213–237.
  2. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012; 111(2): 245–259.
  3. Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013; 34(39): 3028–3034.
  4. Olinic DM, Spinu M, Olinic M, et al. Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. Int Angiol. 2018; 37(4): 327–334.
  5. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003; 107(19): 2512–2518.
  6. Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med. . 2013; 369(10): 954–964.
  7. Wielkoszyński T, Zalejska-Fiolka J, Strzelczyk JK, et al. Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals. Mediators Inflamm. 2018; 2018: 2784701.
  8. Kluk MK. Current review of cardiovascular risk biomarkers. Folia Cardiol. 2017; 12(3): 335–336.
  9. Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017; 14(2): 135–150.
  10. Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015; 131(24): 2104–2113.
  11. Węgierek-Szostak D, Cybulska B. History of research on atherosclerosis. ITEM Publishing Warszawa, Warszawa 2016.
  12. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92(5): 1355–1374.
  13. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999; 281(8): 727–735.
  14. McGill HC, McMahan CA, Zieske AW, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000; 102(4): 374–379.
  15. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92(5): 1355–1374.
  16. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92(3): 657–671.
  17. Sosnowski C, Pasierski T, Janeczko-Sosnowska E, et al. Peripheral artery atherosclerosis in subjects with suspected coronary heart disease. Folia Cardiol. 2005; 12(9): 635–643.
  18. Li YSJ, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech. 2005; 38(10): 1949–1971.
  19. Tymińska A, Kapłon-Cieślicka A. Vascular age – in whom and how to evaluate it? Can we „rejuvenate” the vessels of our patients ? ChSiN. 2019; 16(2): 118–129.
  20. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999; 106(5): 506–512.
  21. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997; 78(3): 273–277.
  22. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101(15): 1767–1772.
  23. Reiss AB, Siegart MN, DeLeon J. Interleukin-6 in atherosclerosis: atherogenic or atheroprotective? Clinical Lipidology. 2017; 12(1): 14–23.
  24. Liu SC, Yi TC, Weng HY, et al. [Prognostic value of myeloperoxidase concentration in patients with acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018; 46(4): 284–291.
  25. Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009; 116(3): 219–230.
  26. Libby P, Jaffer FA, Calfon MA, et al. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis. Nature. 2002; 420(6917): 868–874.
  27. Bruunsgaard H, Skinhøj P, Pedersen AN, et al. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol. 2000; 121(2): 255–260.
  28. Heo SH, Cho CH, Kim HOk, et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol. 2011; 7(2): 69–76.
  29. Lehrke M, Greif M, Broedl UC, et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol. 2009; 8: 50.
  30. Jefferis BJ, Whincup P, Welsh P, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis. 2010; 208(2): 557–563.
  31. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001; 107(10): 1209–1210.
  32. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001; 107(10): 1255–1262.
  33. Varona JF, Ortiz-Regalón R, Sánchez-Vera I, et al. Soluble ICAM 1 and VCAM 1 Blood Levels Alert on Subclinical Atherosclerosis in Non Smokers with Asymptomatic Metabolic Syndrome. Arch Med Res. 2019; 50(2): 20–28.
  34. Shrivastava A, Singh H, Raizada A, et al. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal. 2015; 67(2): 89–97.
  35. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352(1): 29–38.
  36. Patanè S. Growth differentiation factor-15 in chronic heart failure. JACC: Heart Failure. 2018; 6(2): 177.
  37. Wollert KC, Kempf T, Wallentin L, et al. Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz. 2009; 34(8): 594–599.
  38. Wollert KC, Kempf T, Lagerqvist Bo, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007; 116(14): 1540–1548.
  39. Krobot K, Hense HW, Cremer P, et al. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990. Arterioscler Thromb. 1992; 12(7): 780–788.
  40. Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation. 2000; 102(14): 1634–1638.
  41. Duran M, Kalay N, Akpek M, et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology. 2012; 63(6): 448–452.
  42. Enomoto M, Adachi H, Hirai Y, et al. LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone. J Lipids. 2011; 2011: 549137.
  43. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016; 57(4): 526–537.
  44. Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017; 12(Suppl 1): 31–37.
  45. Zhang J, Du R, Peng K, et al. Serum lipoprotein (a) is associated with increased risk of stroke in Chinese adults: A prospective study. Atherosclerosis. 2019; 289: 8–13.
  46. Sadkowska M, Kubica J, Radomski M, et al. Evaluation of serum homocysteine, lipoprotein (a) and oxidized LDL levels in patients before coronarograph. Folia Cardiologica Excerpta. 2004; 11(2): 111–119.
  47. Hartley A, Haskard D, Khamis R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy<sup/>. Trends Cardiovasc Med. 2019; 29(1): 22–26.
  48. Fefer P, Tsimikas S, Segev A, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med. 2012; 13(1): 11–19.
  49. Uno M, Harada M, Takimoto O, et al. Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res. 2005; 27(1): 94–102.
  50. van den Berg VJ, Vroegindewey MM, Kardys I, et al. Anti-Oxidized LDL Antibodies and Coronary Artery Disease: A Systematic Review. Antioxidants (Basel). 2019; 8(10).
  51. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001; 89(12): 1092–1103.
  52. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003; 108(9): 1049–1052.
  53. Erturan I, Köroğlu BK, Adiloğlu A, et al. Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study. Int J Dermatol. 2014; 53(4): 503–509.
  54. Pervanidou P, Chouliaras G, Akalestos A, et al. Increased placental growth factor (PlGF) concentrations in children and adolescents with obesity and the metabolic syndrome. Hormones (Athens). 2014; 13(3): 369–374.
  55. Tang SL, Zhao ZW, Liu SM, et al. Pregnancy-Associated Plasma Protein-A Accelerates Atherosclerosis by Regulating Reverse Cholesterol Transport and Inflammation. Circ J. 2019; 83(3): 515–523.
  56. Oemrawsingh RM, Lenderink T, Akkerhuis KM, et al. CAPTURE investigators. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart. 2011; 97(13): 1061–1066.
  57. Shao D, Lian Z, Di Y, et al. Dietary compounds have potential in controlling atherosclerosis by modulating macrophage cholesterol metabolism and inflammation via miRNA. NPJ Sci Food. 2018; 2: 13.
  58. Stanek A, Cholewka A, Wielkoszyński T, et al. Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors. Oxid Med Cell Longev. 2017; 2017: 9712536.
  59. Stanek A, Cholewka A, Wielkoszyński T, et al. Whole-Body Cryotherapy Decreases the Levels of Inflammatory, Oxidative Stress, and Atherosclerosis Plaque Markers in Male Patients with Active-Phase Ankylosing Spondylitis in the Absence of Classical Cardiovascular Risk Factors. Mediators Inflamm. 2018; 2018: 8592532.
  60. Haroon NN, Paterson JM, Li P, et al. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med. 2015; 163(6): 409–416.
  61. Karakas M, Koenig W. Lp-PLA2 Inhibition-The Atherosclerosis Panacea? Pharmaceuticals (Basel). 2010; 3(5): 1360–1373.
  62. Murakami M, Sato H, Miki Y, et al. A new era of secreted phospholipase A₂. J Lipid Res. 2015; 56(7): 1248–1261.
  63. Reinstadler SJ, Klug G, Feistritzer HJ, et al. Copeptin testing in acute myocardial infarction: ready for routine use? Dis Markers. 2015; 2015: 614145.
  64. Falkentoft AC, Rørth R, Iversen K, et al. MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy. J Am Heart Assoc. 2018; 7(11).
  65. Toutouzas K, Benetos G, Karanasos A, et al. Vulnerable plaque imaging: updates on new pathobiological mechanisms. Eur Heart J. 2015; 36(45): 3147–3154.
  66. Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015; 65(2): 252–256.
  67. Fang J, Madhavan S, Alderman MH. Pulse pressure: a predictor of cardiovascular mortality among young normotensive subjects. Blood Press. 2000; 9(5): 260–266.
  68. Safar ME, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and cardiovascular disease-is it possible to break the vicious circle? Atherosclerosis. 2011; 218(2): 263–271.
  69. Iantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014; 28(2): 169–176.
  70. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008; 5(6): 338–349.
  71. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017; 120(1): 229–243.
  72. Hoshiga M, Arishiro K, Nakakoji T, et al. Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. J Atheroscler Thromb. 2010; 17(7): 705–711.
  73. Kumbhani DJ, Steg PhG, Cannon CP, et al. REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35(41): 2864–2872.
  74. Puri R, Nissen SE, Shao M, et al. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014; 34(11): 2465–2472.
  75. Auscher S, Heinsen L, Nieman K, et al. Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. Atherosclerosis. 2015; 241(2): 579–587.
  76. Gupta S. LDL cholesterol, statins and PCSK 9 inhibitors. Indian Heart J. 2015; 67(5): 419–424.
  77. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012; 380(9858): 1995–2006.
  78. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012; 126(20): 2408–2417.
  79. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308(23): 2497–2506.
  80. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013; 128(19): 2113–2120.